My thoughts and predictions...INNV is not ready to be bought about by anyone and one of the main reasons for this is, that INNV isn't profitable yet and a second reason is that Fluticare hasn't been approved yet.
If INNV became profitable, it probably wouldn't get bought out by a GSK or a Bayer, it would most likely get bought out by a company like herbal life or a company similar to them.
In my opinion, Dr.Damaj heavily overstated 2017 guidance by about 75% and in my opinion, it's best to under promise and over deliver, rather than fail to hit the projected sales numbers. I think Hoffman left, because he realized that at this point, INNV could become a sinking ship.
Fluticare will most likely be approved at the end of 2017. I hope it won't take much money to advertise or sell Fluticare and that the majority of the money is put into manufacturing and distributing Fluticare. I say this because, in my opinion, to some degree, Fluticare should sell itself, due to the brand recognition and due to Fluticare being on the store shelves close to Flonase and the others, so in other words, Fluticare could actually benefit from Flonase advertising.
Hopefully GSK and Bayer won't price their nasal allergy products so low, that it makes it impossible for INNV to make a profit from Fluticare.
Hopefully, Flonase and Clarispray won't be sold in 3rd world countries like INNVs Fluticare will be. Dr.Damaj seems to already have Fluticare manufacturing and sales agreements lined up, just waiting for the slow FDA.
I don't think Q1 or Q2 will cause INNV to go bankrupt if they miss the projected sales, because in a sense INNV is already bankrupt, due to not turning a profit yet. However, drastically missing sales numbers would result in the share price crashing even more.
I like Dr.Damaj's enthusiasm and positive attitude and I hope he makes some good business deals and that INNV becomes majorly profitable soon, because I like the idea of INNV and I am a share holder.
In my opinion, the best way now to get the share price up, is not to buy INNV's stock, but to now focus on buying INNV's products, which I am doing.
If Fluticare was rejected or never approved by the FDA, in theory INNV should be able to survive without it and become profitable without it.
It might be best for us to give INNV 2 more years, rather than 2 more Q's to make a better judgement and hopefully INNV will be around for at least another 2 years.
God Bless us all and Happy Easter!
AI
